Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0432222 (SEM)
 47,337 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We have explored scid mice as an in vivo model to study lymphocyte function and autoantibody production in patients with autoimmune thyroiditis and thyroid peroxidase (hTPO) autoantibodies. Patient's peripheral blood mononuclear cells (PBMC) were transplanted into scid mice via intraperitoneal injections and human immunoglobulin G (hIgG) and thyroid autoantibody levels in the murine sera were monitored for a minimum of 3 months after transplantation. Human IgG reached maximum serum levels of > 3,000 micrograms/ml (mean +/- SEM = 1,199 +/- 354 micrograms/ml) after an average of 6.5 weeks. In reconstituted mice (hereafter named At-Scid-hu) substantial titers of anti-hTPO of up to 0.51 (ELISA index, normal range < 0.02) were observed over a period of 1-2 months, followed by a gradual decline. Immunization of AT-Scid-hu mice with immunogenic, recombinant human hTPO (rec-hTPO) failed to enhance hTPO-Ab levels. Furthermore, there was no correlation between the magnitude of human IgG in the murine serum and concomitant levels of anti-hTPO. Murine thyroid function was unaffected by the transplantation of PBMC, as evidenced by normal serum thyroxine (T4) levels, and lack of specific pathologic changes in the thyroid. These data indicate, for the first time, the potential for longer-term human thyroid autoantibody secretion in the scid mouse reconstitution model allowing for further investigation of the regulatory factors inpinging on the human B cells surviving in the murine environment.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Characteristics of long-term human thyroid peroxidase autoantibody secretion in scid mice transplanted with lymphocytes from patients with autoimmune thyroiditis. 142 61

We have studied by flow cytometric analysis the antigen specific activation of CD4+ (helper/inducer) T lymphocytes by purified human thyroid peroxidase (TPO). Peripheral blood mononuclear cells were obtained from 26 patients with Graves' disease (GD), 16 with Hashimoto's thyroiditis (HT), 7 with nontoxic nodular goiter (NG), and 14 normal subjects (N). Cells were cultured for 7 days in the presence or absence of TPO at final concentrations of 3, 30, and 300 ng/mL. When harvested, cells were reacted with an FITC-conjugated anti-CD4 and a PE-conjugated anti-HLA-DR murine monoclonal antibodies. The percentage of HLA-DR+ CD4+ cells (activated CD4+ cells) was determined by a flow cytometer. In the absence of TPO, CD4+ cells had been activated without any specific stimulant. This is known as the autologous mixed lymphocyte reaction (AMLR). In the AMLR, CD4+ cells from GD and HT were less activated compared to those from NG and N. Results of TPO-specific activation were expressed as an incremental increase of activated CD4+ cells (II) (percentage of activated CD4+ cells cultured with TPO minus percentage of activated CD4+ cells cultured without TPO). II of N, GD, HT, and NG were 0.37 +/- 0.21, 2.20 +/- 0.45,** 2.0 +/- 0.66,* and 0.35 +/- 0.27 (mean +/- SEM), respectively (**p less than 0.01; *p less than 0.05 vs N). When patients were further subdivided, the highest mean II was found in patients with hyperthyroid GD (p less than 0.01), followed by euthyroid HT (p less than 0.05) and euthyroid GD (p less than 0.05), however there was no significant difference between hypothyroid HT and N. In conclusion (1) AMLR reactivity of CD4+ cells from GD and HT was impaired, (2) however, CD4+ cells from both GD and HT were significantly more induced by TPO compared to N, and (3) this induction depends, in part, on the in vivo thyroid status.
 ...
PMID:Studies of CD4+ (helper/inducer) T lymphocytes in autoimmune thyroid disease: demonstration of specific induction in response to thyroid peroxidase (TPO) in vitro and its relationship with thyroid status in vivo. 168

Severe combined immunodeficient (SCID) mice were injected with peripheral blood mononuclear cells (PBMC) from normal individuals and 14 out of 18 had detectable serum human (h) IgG (maximum levels providing a mean +/- SEM 934 +/- 213 micrograms/ml) and IgM (253 +/- 93 micrograms/ml) at 3-6 weeks after transplantation. Serum human immunoglobulin levels were maximum 6-12 weeks after transplantation and declined to low levels over the subsequent 5 months. Human B cells constituted up to 10% and human T cells up to 40% of cells in the peripheral circulation and spleens of these animals 2-3 weeks after transplantation, PBMC, or intrathyroidal (IT) lymphocytes, from 6 patients with Graves' disease and high serum levels of thyroid autoantibodies were transplanted into 30 SCID mice (Graves' SCID-hu). Although serum human immunoglobulins were observed in only low amounts in the animals receiving IT lymphocytes (n = 4), increased levels of hIgG or hIgM were more easily detectable in 19 Graves' SCID-hu mice that received PBMC. The Graves' SCID-hu mice had significantly lower mean levels of hIgG and hIgM than those observed following transplantation of normal PBMC (mean maximum 328 +/- 113 and 32 +/- 21 micrograms/ml, respectively). Six of these 19 mice had detectable human autoantibody to thyroid peroxidase (TPO, as microsomal antigen) between 3 and 8 weeks after transplantation, with titers ranging from 0.05 to 0.39 (normal SCID-hu serum less than 0.02 ELISA Index). No abnormal thyroid hormone (T4 and T3) levels or thyroiditis was seen when compared to normal SCID-hu mice. Immunization of reconstituted SCID mice with recombinant immunoactive human TPO antigen failed to initiate anti-TPO in normal PBMC-treated mice nor did it increase the titer of human anti-TPO in the anti-TPO positive animals. In conclusion we successfully established human thyroid autoantibody secretion in the SCID-hu mouse and characterized the transient nature of the model. Further studies will be required to achieve successful antigen presentation in this system.
 ...
PMID:The SCID-hu mouse and thyroid autoimmunity: characterization of human thyroid autoantibody secretion. 207 May 73

Recently, we converted a thyroid peroxidase (TPO)-specific human autoantibody Fab (SP1.4) into an IgE molecule (IgE-SP1.4) which permits antigen capture via Fc epsilon receptors on B cells and presentation to T cells. An important question which arose was whether IgE class TPO autoantibodies are present in vivo. By ELISA, TPO autoantibodies of IgG1 and IgG4 subclasses, but not IgE, were readily detectable in patients' sera. However, such negative data were not definitive because high concentrations of IgG class TPO autoantibodies could obscure the presence of much lower concentrations of IgE class autoantibodies. We, therefore, established a specific assay based on IgE "capture" to remove other isotypes before incubation with TPO. In an initial survey, 125I-TPO binding was higher in sera from 16 patients with autoimmune thyroid disease than in 6 controls (8.4 +/- 0.8% versus 0.7 +/- 0.2%; mean +/- SEM). Unlabeled TPO (10(-8) M) inhibited 125I-TPO binding by patients' (but not controls') IgE. Further, TPO binding by IgE-SP1.4 was unaffected by IgG class TPO autoantibodies. Titers of IgE class TPO autoantibodies were low, detectable at a 1/60 dilution in 4/5 sera studied. In a larger series, IgE class TPO autoantibodies were present in 13 of 18 Graves' and in 12 of 17 Hashimoto patients (sera diluted 1/6). Sera were considered to be positive with TPO binding greater than the mean + 3 SD of values for 23 control sera (1.8%). In conclusion, we provide the first evidence for TPO autoantibodies of IgE class in patients with autoimmune thyroid disease. Because of their low concentration, these autoantibodies are unlikely to play a role in antigen presentation in vivo. However, their presence strengthens the link between autoimmune thyroid disease and immune responses involving TH2 cells.
 ...
PMID:Thyroid peroxidase autoantibodies of IgE class in thyroid autoimmunity. 900 Apr 84

Thyroid glands affected by Graves' disease (GD) show striking lymphocytic infiltration, mainly by CD45RO(+) T cells. The mechanisms by which the various lymphocytic subsets are recruited and maintained in the thyroid are unknown. RANTES (regulated on activation, normal T cells expressed and secreted) in interaction with its receptors (CCR1, CCR3, CCR4 and CCR5) may be one of the favorite chemokines involved in the cell trafficking and maintenance. RANTES messenger RNA (mRNA) was quantified in the thyroid tissue of 16 patients with GD and 7 patients with thyroid autonomy (TA), using competitive RT-PCR. We found a clear correlation between the RANTES mRNA level and 1) the degree of T-cell infiltration (r = 0.68), and 2) the level of serum antibodies to thyroid peroxidase (r = 0.76) in GD but not in TA patients. There was no difference between the autonomous nodules and the quiescent surrounding tissue in TA patients. To define the cellular source of RANTES mRNA and protein, we examined various thyroid-derived cells. Lymphocytes showed a markedly higher basal RANTES mRNA and protein level (mean +/- SEM; pg/mL, n = 3; 140 +/- 30) than thyrocytes (12 +/- 5) and fibroblasts (9 +/- 2). Lymphocyte stimulation with PMA enhanced RANTES secretion significantly (4490 +/- 200). Fibroblasts responded to stimulation with interleukin 1 (530 +/- 220) and tumor necrosis factor alpha (2780 +/- 1790), whereas thyrocytes did not. However, some thyroid carcinoma cell lines showed very high basal and stimulated RANTES expression. Lymphocytes expressed the mRNA of all chemokine receptors that bind RANTES. The number of CCR3(+) and CCR5(+) T cells was significantly higher in thyroid-derived leukocytes than in those in the peripheral blood stream. We conclude that RANTES expression, mainly by lymphocytes, is perhaps involved in the maintenance of lymphocytic infiltration and, therefore, in the autoimmune responses in GD.
 ...
PMID:Expression and regulation of regulated on activation, normal T cells expressed and secreted in thyroid tissue of patients with Graves' disease and thyroid autonomy and in thyroid-derived cell populations. 1113 39

Hypothyroidism is an autoimmune disease associated with underactive thyroid gland. In this study, a dual effect polymeric system was designed to release Cepharanthine (CEP) to block T cell activation and Selenium (Se) to decrease the anti-thyroid peroxidase (TPOAb) concentration in order to treat hypothyroidism. For this purpose, poly(ethylene-vinyl acetate) (PEVA) and polyethylene glycol (PEG) nanoparticles (NPs) including CEP were synthesized by emulsion solvent evaporation method and they were loaded to polyurethane (PU)/PEG-PUSe-PEG block copolymer blends which were fabricated by particulate leaching technique as porous sponges. Fourier-Transform Infrared (FTIR), Raman, and Nuclear Magnetic Resonance (NMR) analysis showed successful synthesis of PEG-PUSe-PEG block copolymer. A long-term zero-order release profile was obtained for CEP. Se release rate from matrices showed an oxidative stress-mediated release which can be used to adjust Se amount. According to MTS results conducted by NIH 3T3 fibroblasts, both NPs and matrices have no adverse effect on cell viability. Fluorescence microscopy and SEM images confirm the MTS results. The dual release system has potential to be effectively used in long-term treatment of hypothyroidism by addressing both auto-immune response and hormone regulation.
 ...
PMID:A multifunctional long-term release system for treatment of hypothyroidism. 3178 40